Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717-454, an insulin growth factor receptor inhibitor, in combination with everolimus, an MTOR inhibitor

Target Oncol. 2014 Mar;9(1):73-9. doi: 10.1007/s11523-013-0267-8. Epub 2013 Feb 21.

Authors

Swati Sikaria¹, Josefine Heim-Hall, Elizabeth H Diaz, Ronald Williams, Kamelesh Sankhala, Brenda Laabs, Monica Mita

Affiliation

¹ Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SCCT Mezzanine MS 35, 8700 Beverly Blvd, Los Angeles, CA, 90048, USA.

PMID: 23430345
DOI: 10.1007/s11523-013-0267-8

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Everolimus
Giant Cell Tumors / diagnosis
Giant Cell Tumors / drug therapy*
Giant Cell Tumors / pathology
Humans
Joint Capsule / pathology
Male
Middle Aged
Neoplasm Metastasis
Receptors, Somatomedin / antagonists & inhibitors
Receptors, Somatomedin / immunology
Shoulder Joint / pathology*
Sirolimus / administration & dosage
Sirolimus / analogs & derivatives*
Soft Tissue Neoplasms / diagnosis
Soft Tissue Neoplasms / drug therapy*
Soft Tissue Neoplasms / pathology
TOR Serine-Threonine Kinases / antagonists & inhibitors
Tendons / pathology
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Receptors, Somatomedin
Everolimus
MTOR protein, human
TOR Serine-Threonine Kinases
robatumumab
Sirolimus